¹**Molecular Epidemiology and Diversity of SARS-CoV-2 in Ethiopia, 2020-** ²**²⁰²²**

-
- 4
- 5 Abay Sisay^{1, 2, ¶,*}, Derek Tshiabuila^{3, 4,¶} Abraham Tesfaye^{1,5}, Gerald Mboowa⁶, Samuel O. Oyola⁷,
5. Sefenias Kifle Tesema⁶, Chend Baxter^{3,4,} Darren Martin^{3,4,} Pichard Lesselle^{3,4,} Hourijvah Tegally
- Sofonias Kifle Tesema⁶, Cheryl Baxter^{3,4}, Darren Martin^{3,4}, Richard Lessells^{3,4}, Houriiyah Tegally^{3,4},
7 Stephanie van Wyk^{3,4}, Manika Mair^{3,4}, Jappifer Ciandhari ^{3,4}, Sureshnee Billov^{3,4}, Lavenye Si
- Stephanie van Wyk3,4, Monika Moir3,4, Jennifer Giandhari 3,4, Sureshnee Pillay3,4, Lavanya Singh3,4 ⁷,
- Yajna Ramphal^{3,4}, Arisha Maharaj^{3,4},Yusasha Pillay^{3,4}, Akhil Maharaj ^{3,4}, Yeshnee Naidoo^{3,4},
9 Upasana Ramphal^{3,4}, Lucious Chabuka^{3,4} .Eduan Wilkinson^{3,4}. Tulio de Oliveira^{3,4,8}, Adev Fe
- 9 Upasana Ramphal^{3,4}, Lucious Chabuka^{3,4} ,Eduan Wilkinson^{3,4}, Tulio de Oliveira^{3,4,8}, Adey Feleke
10 Desta² and James E. San^{3,4, *}
- Desta² and James E. San^{3,4, $*$}
- 11
- 12 ¹Department of Medical Laboratory Sciences, College of Health Sciences, Addis Ababa University,
12 Medie Ababa Ethiopia
- 13 Addis Ababa, Ethiopia
14 ²Department of Microl
- 14 ²Department of Microbial, Cellular, and Molecular Biology, College of Natural and Computational 15 Sciences Addis Abobe University Addis Abobe Ethiopic
- 15 Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
16 ³KwaZulu-Natal Research Innovation and Sequencing Pla
- ³ KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), Nelson R Mandela School
17. of Medicine University of KwaZulu Natal Durban, South Africa
- 17 of Medicine, University of KwaZulu-Natal, Durban, South Africa.
18 ⁴Centre for Epidemic Response and Innovation (CERI). School
- 18 ⁴ Centre for Epidemic Response and Innovation (CERI), School of Data Science and Computational
19 Thinking Stellanboach University Stellanboach South Africa
- 19 Thinking, Stellenbosch University, Stellenbosch, South Africa.
20 ⁵Diagnostic Unit, Center for Innovative Drug Development ar
- ⁵ Diagnostic Unit, Center for Innovative Drug Development and Therapeutic Trials for Africa, CDT-
21 Defica Addis Ababa Ethiopia
- 21 Africa, Addis Ababa, Ethiopia
22 ⁶ Institute of Pathogen Genom
- 22 ⁶ Institute of Pathogen Genomics, Africa Center for Disease Control and Prevention (Africa CDC), 22 and Africa CDC),
- 23 Addis Ababa, Ethiopia.
24 ⁷International Livestock
- Z4 ⁷International Livestock Research Institute (ILRI), Nairobi, Kenya.
25 ⁸Department of Global Health, University of Washington: Seattle, I
- ⁸Department of Global Health, University of Washington; Seattle, USA.
²⁶
- 26
27
- 28 ^{*}Corresponding author(s): Abay Sisay (<u>abay.sisay@aau.edu.et</u>), San E James
29 (sanemmanueljames@gmail.com)
- (sanemmanueljames@gmail.com)
- 30 These authors contributed equally to this work

³¹**Abstract**

³²Ethiopia is the second most populous country in Africa and the sixth most affected by

³³COVID-19 on the continent. Despite having experienced five infection waves, >499 000 34 cases, and \sim 7 500 COVID-19-related deaths as of January 2023, there is still no 35 detailed genomic epidemiological report on the introduction and spread of SARS-CoV-2 36 in Ethiopia. In this study, we reconstructed and elucidated the COVID-19 epidemic 37 dynamics. Specifically, we investigated the introduction, local transmission, ongoing 38 evolution, and spread of SARS-CoV-2 during the first four infection waves using 353 39 high-quality near-whole genomes sampled in Ethiopia. Our results show that whereas ⁴⁰viral introductions seeded the first wave, subsequent waves were seeded by local 41 transmission. The B.1.480 lineage emerged in the first wave and notably remained in 42 circulation even after the emergence of the Alpha variant. The B.1.480 was out-43 competed by the Delta variant. Notably, Ethiopia's lack of local sequencing capacity was 44 further limited by sporadic, uneven, and insufficient sampling that limited the 45 incorporation of genomic epidemiology in the epidemic public health response in ⁴⁶Ethiopia. These results highlight Ethiopia's role in SARS-CoV-2 dissemination and the 47 urgent need for balanced, near-real-time genomic sequencing.

48

⁴⁹**Keywords**: COVID-19, Molecular epidemiology, SARS-CoV-2, Whole Genome Sequence, Ethiopia

⁵⁰**Introduction**

51 Ethiopia is a landlocked country in Eastern Africa $[1, 2]$. It is further one of the most 52 populous countries on the continent, and following the global trend, has accordingly 53 endured severe economic and healthcare burdens due to the ongoing COVID-19 54 pandemic [3,4]. On 13 March 2020, the Federal Ministry of Health in Ethiopia reported ⁵⁵its first COVID-19 case in Addis Ababa. By February 2022, Ethiopia had recorded 56 approximately 494,760 confirmed cases and 7,572 deaths $[5, 6]$. Despite various 57 pandemic mitigation strategies implemented by the government (Table S1), the 58 number of COVID-19 cases continued to rise. Ethiopia currently constitutes one of the 59 most severely affected countries on the African continent. On the $8th$ of April 2020, the ⁶⁰Ethiopian government declared a 5-month national state of emergency to control and 61 contain the growth rate of the local epidemic and support mitigation mechanisms $[7,8]$. 62 These emergency measures included the closing of schools and other academic 63 institutes, restrictions on large gatherings, and implementation of mask mandates. ⁶⁴These restrictions were complemented by encouraging social distancing and hand ⁶⁵washing using multimedia campaigns [7, 9, 10]. While genetic diversity is a major 66 driver of epidemic dynamics, until now, no detailed molecular epidemiology and 67 genetic diversity analyses of SARS-CoV-2 have been performed in Ethiopia. To 68 address this problem, we analyzed 353 high-quality near complete SARS-CoV-2 ⁶⁹genomes sampled in Ethiopia against a globally representative set to characterize the 70 introduction, transmission, and spread of SARS-CoV-2 in Ethiopia.

⁷¹**Materials and Methods**

⁷²**Ethical Consideration**

73 This study was reviewed and got approved by Addis Ababa University, College of 74 Health Science Institutional Review Board (IRB) (IRB # 029/20/Lab), IRB of the 75 Department of Medical Laboratory Sciences, Addis Ababa University (reference #-⁷⁶MLS/174/21), IRB office of Addis Ababa City Administration Health Bureau, 77 AAPHREML (Reference #- AAHB/4039/227) and also from Addis Ababa University, ⁷⁸College of Natural and Computational Science IRB (IRB #- CNCSDO/604/13/2021), 79 by Yekatit 12 Hospital Medical College (IRB protocol # 75/20) and also reviewed and

⁸⁰approved by the Federal Democratic Republic of Ethiopia National Ethics Committee 81 at the Ministry of Science and Higher Education (MoSHE) (IRB #021/246/820/21).

⁸²**Study Design, Period, and Setting**

⁸³We leveraged samples collected from confirmed Ethiopian SARS-CoV-2 cases 84 recorded between July 2020 and February 2022 to produce whole and near-whole
85 denomes. Specifically, whole genome sequencing (WGS) was carried out on a subset genomes. Specifically, whole genome sequencing (WGS) was carried out on a subset 86 of RT-PCR positive samples (N=353) collected during the first four waves of the 87 pandemic in Ethiopia. The genomes can be further classified according to the 88 sampling strategy, i.e., community surveillance $(n=170)$, contacts of confirmed cases 89 (n=78), and suspected cases (symptomatic but yet to be confirmed by laboratory
90 results) (n=105), (Figure S2), Nasopharyngeal (NP) swab specimens were collected results) (n=105), (Figure S2). Nasopharyngeal (NP) swab specimens were collected 91 using 2ml of Viral Transport Medium (VTM), (China, Miraclean Technology Co., Ltd., 92 www.mantacc.com) from patients in Addis Ababa, Amhara, Oromia, and the Southern ⁹³Nations, Nationalities, and Peoples Regional States (provinces) of the country. The ⁹⁴number of samples selected from each region was based on the epidemic distribution 95 of the diseases across the country (Figure $S3$). These areas are known to have high 96 population densities and cover almost three-quarters of the country's inhabitants $[11, 16]$ 97 12]. Only samples with cycle threshold (Ct) values under 30 were considered viable 98 and submitted for sequencing

⁹⁹**Quality Assurance**

¹⁰⁰We implemented a comprehensive total quality management system to ensure the 101 quality of our sequence data throughout the process (from pre-analytical to post-102 analytical). The specimens with RT-PCR Ct values <30 were stored in a −80°C freezer 103 at Arsho Advance Medical Laboratories Plc: an ISO 15189 accredited laboratory [13].

¹⁰⁴**RNA Extraction and Viral Detection**

¹⁰⁵Extraction, purification, and viral detection using RT-PCR were done as per our 106 previous work and respective manufacturer recommendations [14-17]. Viral detection 107 was done at the Ethiopian Public Health Institute (EPHI), AAPHREM center
108 Iaboratory, Yekatit 12 Hospital, Arsho-medical-laboratory, and Addis-Ababa-University. laboratory, Yekatit 12 Hospital, Arsho medical laboratory, and Addis Ababa University.

109 These were amongst the established RT-PCR laboratories where the majority of 110 COVID-19 testing was performed. SARS-CoV-2 positive samples from the first three 111 waves of the pandemic were shipped to CERI/KRISP (South Africa), and from the 112 fourth wave (103) to ILRI (Kenya) for whole genome sequencing. All biological 113 specimens were transported following a triple packaging biosafety and biosecurity 114 protocol.

¹¹⁵**Next-Generation Sequencing of SARS-CoV-2**

116 WGS was performed using either the Illumina or the Oxford Nanopore Technology ¹¹⁷(ONT) sequencing platforms. Briefly, RNA was extracted on the automated Chemagic ¹¹⁸360 system (Perkin Elmer) as per the manufacturer's instructions. Samples were lysed 119 using proteinase K and bound using silica magnetic beads. Beads were then washed 120 and the RNA was eluted and stored at -80 °C until use. SuperScript IV reverse 121 transcriptase (Life Technologies) was then used, in combination with random hexamer 122 primers, to convert extracted RNA to complementary DNA. Gene-specific multiplex 123 PCR using the ARCTIC protocol was then performed. PCR was used to generate 400 124 base pair (bp) amplicons, with an overlap of 70 bp to cover the 30 kilobases (kb) 125 SARS-CoV-2 genome. PCR products were purified using AmpureXP purification 126 beads (Beckman Coulter, High Wycombe, UK), and quantification was performed 127 using the Qubit double-strand DNA (dsDNA) High Sensitivity Assay Kit on a Qubit 4.0 128 instrument (Life Technologies). These libraries were then used for Illumina MiSeq and 129 ONT GridION sequencing.

130 Illumina MiSeq indexed paired-end libraries were prepared using the Nextera DNA 131 Flex Library Prep Kits (Illumina) as per the manufacturer's instructions. Tagmented 132 amplicons were barcoded with a unique barcode using the Nextera CD Indexes ¹³³(Illumina), which allows for library pooling. Prior to pooling, libraries were normalized 134 to 4 nM and pooled, then denatured using sodium acetate. Pooled libraries were then 135 diluted and spiked with 1 % PhiX Control v3 and sequenced using a 500-cycle v2 136 MiSeq Reagent Kit on the Illumina MiSeq instrument (Illumina, San Diego, CA, USA) ¹³⁷[18. ONT Native Barcoding Expansion kits were used for ONT GridION sequencing 138 according to the manufacturer's protocol. Samples were multiplexed on the FLO-

139 MIN106 flowcells and ran on the GridION X5. The MinKNOW software was used to 140 monitor sequencing performance in real-time [19].

141

¹⁴²**Metadata Management**

¹⁴³Clinical and demographic metadata were collected from the confirmed cases using a 144 structured assessment tool by trained healthcare professionals at the triage of the 145 health facilities and from the community. A medical record number (MRN) was 146 assigned to each patient as a unique anonymous identifier as their names were not 147 linked to the MRNs submitted to sequence repositories such as GISAID, ¹⁴⁸EPI_SET_221214bg doi: 10.55876/gis8.221214bg.

¹⁴⁹**Sequence Alignment, Assembly, and Phylogenetic Analysis**

150 Fastg sequences were assembled using Genome Detective 1.133 (http://www. 151 genomedetective.com) [20] and the Coronavirus tool [21]. The initial assemblies 152 obtained from Genome Detective were visualized and manually edited using Geneious 153 Prime version 2022.2.2 $[22,23]$ to remove low-quality mutations. Nextclade was used 154 to determine the quality control profiles of the sequences. The quality metrics used for 155 the sequences in this study included genome coverage greater than 80%, ensured the 156 removal of unknown frameshifts, stop codon, and clustered mutations. Additionally, 157 submissions with exceedingly high and missing data (N) <3000Ns) were excluded 158 from downstream analyses. Nextclade was further employed to assign clades and 159 lineage classifications to the sequences $[24,25]$. Sequences that met these quality 160 control thresholds were deposited in the GISAID (https://www.gisaid.org/) database, ¹⁶¹EPI_SET_221214bg doi: 10.55876/gis8.221214bg].

162 To present a comprehensive analysis of the genomic epidemiology of SARS-CoV-2 in ¹⁶³Ethiopia, the genomes generated in this study were combined with a globally 164 representative set of genomes ($n= 13589$) that were sampled during the same period. ¹⁶⁵All samples from the bordering countries to Ethiopia were included in the analysis to 166 better model the relationship between Ethiopia and its Neighbors and infer cross-167 border transmission. This did not cause a sampling bias as these countries were 168 already characterized by a low number of sequences. Additionally, all global 169 sequences belonging to the B.1.480 lineage which was predominant in Ethiopia and 170 remained in circulation across the first three waves were included. Together, this 171 resulted in a dataset of 13,942 genomes. Acknowledgment was given to the 172 sequencing laboratories that contributed to the analysis set (EPI SET 221214bg, 173 DOI: 10.55876/gis8.221214bg).

174 Sequences were aligned using NextAlign [26] to obtain a good codon alignment of the 175 sequences. A maximum likelihood tree topology was inferred from the resulting 176 alignment in IQTREE 2 $[27]$ using the General Time Reversible model of nucleotide 177 substitution [28] The inferred phylogeny was used along with the associated metadata 178 that was obtained from GISAID, to map discrete geographical locations to each of the 179 tips and infer locations for the internal nodes. This was done using the Mugration 180 package extension of TreeTime [29]. A custom Python script was then used to count 181 the number of discrete changes occurring as we transcended the topology from the 182 root towards the tips. In essence, this provided a crude estimate of the number and 183 timing of viral exchanges (import-export) between Ethiopia and the rest of the world.

¹⁸⁴**Data Analysis and Visualization**

185 The data were analyzed and visualized using R version 4.2.0 using available 186 packages and custom scripts. The tree was visualized using the R package ggtree 187 version 3.0.4[30].

189

190

191

¹⁹²**Results**

193

194 **Socio-demographic Characteristics of the Study Participants along with SARS-**¹⁹⁵**CoV-2 Variants of Concerns (VOCs)**

¹⁹⁶A total of 1300 nasopharyngeal swabs were collected from four provinces in the 197 country. These samples included 181 (51.3%) specimens obtained from female 198 patients while 172 (48.7%) were sampled from male patients. The patient ages ranged ¹⁹⁹between 2 and 86 years old, although most of the cases were between 21- and 30- 200 year-old patients, with an overall estimated median age of 31.45 (IQR=26-46) years. 201 More than 77 % of the patients presented with mild cases (Table 1). Of these, we 202 discarded 300 due to their high CT values (i.e., $>$ 30). The remaining 1000 samples 203 were subjected to the library preparation and 808 yielded sufficient RNA for WGS 204 following RT-PCR amplification. The WGS resulted in 353 SARS-CoV-2 sequences 205 that passed bioinformatics quality controls. (i.e., with genome coverage greater than ²⁰⁶80%, a limited number of private mutations, no clustered mutations, and no misplaced 207 stop codons). Figure S2 illustrates a detailed breakdown of the sample processing. 208 During the study period, a combination of genetically distinct SARS-CoV-2 lineages 209 were identified. The majority of these assemblies (91.7%) were classified as variants 210 of concern (VOC).

²¹¹**Local Epidemic Dynamics**

212 To illuminate the local epidemic dynamics in Ethiopia, we performed an in-depth study 213 of the 353 high-quality SARS-CoV-2 genomes (Figure 1). The study period 214 corresponds with the first four COVID-19 waves experienced in the country. The first 215 buave occurred between August and September 2020, the second between February
216 buand March 2021, and the third occurred between July and October 2021, Each wave and March 2021, and the third occurred between July and October 2021. Each wave 217 was characterized by higher rates of transmission and fatality than previous waves 218 (Figure 1A). Notably, the third wave was more severe and lasted longer than the two 219 previous waves. The fourth wave began with an uptick in cases in December 2021 220 and continued to February 2022. The wave was characterized by the highest rates of

221 community transmission yet observed (Figure 1A). However, compared to the global 222 trend at the time, it resulted in fewer deaths.

223 Across the four waves, the peak number of new cases remained relatively consistent 224 with the first and third waves reflecting a 7-day rolling average of approximately 1500 225 individuals. The second wave had a slightly higher 7-day rolling average of 2000 226 individuals whilst the fourth had the highest at over 4000 individuals (Figure 1A). The
227 number of new deaths across each wave had a similar trend to the average number of number of new deaths across each wave had a similar trend to the average number of 228 new cases with the second and third waves having the highest number of new deaths 229 at approximately 50 individuals per day (Figure 1B). Vaccine rollout commenced in 230 April 2021 in Ethiopia and by February 2022, approximately 25% of the population had 231 Freceived at least one dose of Oxford-AstraZeneca or Sinopharm COVID-19 vaccines
232 Freque 1B). (Figure 1B).

²³³**Phylogenetic reconstruction and Variant Detection in Ethiopia**

²³⁴Ancestral state reconstruction showed that viral imports into Ethiopia occurred 235 between August 2020 and January 2021, with the majority of importation events 236 occurring in August 2020 [n=123], December 2020 [n=130], and January 2021 [n=169] ²³⁷(Figure 1C). In comparison, September and November 2020 corresponded with the 238 highest numbers of inferred SARS-CoV-2 exports from Ethiopia (n=109 and n =137, 239 respectively; Figure 1D, Figure S4). The majority of inferred importation events were 240 from Eastern Africa [n=324] origins, whereas most of the inferred exportation events 241 were generally attributed to Western European and Asian origins (n=20 and n=141 242 respectively). Overall, we identified 570 importation and 446 exportation events during 243 the study period.

²⁴⁴Our early sequences sampled between November and December 2020 represented 245 two lineages, B.1/B.1.1 and B.1.480, with most of the sequences classified as 246 B.1/B.1.1. These two lineages continued to circulate throughout the first quarter of 247 2021 (January to March). The B.1.480 lineage was thought to have originated in ²⁴⁸Ethiopia. In our study, 21 genome assemblies were assigned to this emerging lineage. ²⁴⁹(EPI_SET_230126dy, doi: 10.55876/gis8.230126dy). Phylogenetic inference

250 supported that this lineage was a monophyletic clade. Despite its persistence in 251 Ethiopian populations for an extended period, this variant did not disseminate globally 252 as was observed for other VOC and ultimately only constituted only 473 GISAID 253 submissions during the progression of the pandemic, EPI_SET_230126vf, doi: ²⁵⁴10.55876/gis8.230126vf. Nevertheless, according to GISAID submissions, this lineage 255 was detected in neighboring countries such as Kenya, Somalia, Djibouti, and Guinea-256 Bissau. This lineage was further disseminated internationally where it was detected in 257 Australia, the United States of America, Canada, Japan, Israel, Hong Kong, and South 258 Korea. This period was followed by the detection and rise to dominance of VOCs in 259 the country.

260 In January 2021, the first case of the Alpha variant was detected. Within a span of 261 one month, it had reached equal prevalence to B.1/B.1.1. The B.1.1 continued to 262 circulate in low prevalence with the cases detected until May 2021. Alpha was 263 however short-lived as the Delta variant emerged. The Delta variant was first detected 264 in February 2021. Thereafter, it quickly outcompeted all other lineages (Figure S5). By 265 April, it had become the most prevalent variant. The predominant Delta variant sub 266 lineages where $AY.120$ (116 sequences, 46.4%) and B.1.617.2 (50 sequences, 20%). 267 The Delta variant seeded the $3rd$ wave in Ethiopia. Although no sequence data was 268 available from September to December 2021, the majority of the cases sampled and 269 sequenced from January 2022 were attributed to the Omicron lineage (Fig 1A & 2A). 270 Over the course of the study period, we identified 37 distinct lineages in circulation
271 (Fig 2 A, Fig 2B, Figure S6). $(Fig 2 A, Fig 2B, Figure S6).$

272 The phylogenetic reconstruction revealed close relatedness (not substantially 273 observed levels of divergence) among sequences assigned to the same lineages. 274 However, this observation did not hold for samples assigned to the Delta variant ²⁷⁵(Figure 2C). Sequences attributed to the Delta variant showed greater variation in 276 sequence composition. Moreover, higher levels of phylogenetic clusters, associated 277 with community transmission, were observed during the study period. Phylogenetic 278 clusters and associated community transmission events were also observed for the 279 Omicron lineage (Figure 2C).

²⁸¹**Discussion**

282 In this study, we investigated the introduction of SARS-CoV-2 viral lineages, local 283 transmission, and its evolution within Ethiopia. This study represents the first of its 284 kind as no other molecular epidemiology investigation has been conducted for this 285 country and provided an overview of the pandemic progression relative to a global 286 context. Our results show that SARS-CoV-2 was introduced into Ethiopia on multiple 287 occasions, with most introductions originating from Eastern African countries. These 288 introductions included 37 distinct SARS-CoV-2 lineages and four VOCs, namely 289 Alpha, Beta, Delta, and Omicron lineages. Of the introduced lineages the B1.480 290 persisted and remained in circulation from December 2020 to August of 2021.

291 Our findings show that as of February 2022, Ethiopia had experienced four distinct 292 COVID-19 waves. Although various preventive strategies such as the mandatory 293 wearing of masks, and media awareness campaigns were adopted together with a 294 mandatory 14-day self-quarantine regulation for all international travelers arriving in 295 the country [5], Ethiopia remained vulnerable to SARS-CoV-2 introductions. Our 296 results showed that despite preventative measures viral introduction events continued 297 to occur and were followed by community transmission. This in turn facilitated a 298 continued increase in case numbers. This could be attributed to the partial restriction
299 of public transport which is an import mode of SARS-CoV-2 transmission [5, 31]. of public transport which is an import mode of SARS-CoV-2 transmission $[5, 31]$. 300 During lockdowns, the operation of economic activities did not cease as they were 301 deemed necessary to support the already fragile economic and socioeconomic 302 situation of the country. This made lockdowns ineffective in preventing local 303 transmission and epidemic growth. By 30 April 2021, the total number of cases and
304 deaths had surpassed 257442 and 3688. respectivelv [1, 3], and has currentlv deaths had surpassed 257442 and 3688, respectively $[1, 3]$, and has currently 305 increased to >499000 and 7500 deaths.

306 Our findings show that Ethiopia experienced poor sampling mostly limited to Addis ³⁰⁷Ababa. Temporal sampling was also hampered by periods of limited sampling and, 308 lack of local sequencing capacity resulting in substantial delays that in turn may cause

309 the degradation of samples during transit. Yet, an in-depth understanding of the 310 COVID-19 pandemic progression in Ethiopia remains of paramount importance to aid 311 the navigation of ongoing and future pandemics within these regions $[32]$. Indeed, ³¹²Ethiopia has had several viral outbreaks in recent history, in addition to the ongoing 313 COVID-19 pandemic. Some of the notable outbreaks include Measles, and mosquito-314 borne illnesses such as Yellow fever, Chikungunya, and Malaria [32, 33]. Thus, 315 scaling up of local and regional pathogen genomic sequencing capacity and a robust 316 pathogen genomic surveillance infrastructure is thus required to shorten the 317 turnaround time and to allow for early public health response [34]. Additionally, during 318 the onset of the pandemic, a survey on outbreak readiness highlighted a dire need for 319 not only pathogen surveillance in Ethiopia but Ethiopia further scored only 52% on the 320 Ready Score index, which shows that the nation still has progress to be made to 321 increase case tracing and identification, increase healthcare and testing facilities,
322 provide clear operational quidelines on preventive measures across various provide clear operational guidelines on preventive measures across various 323 organizations, businesses, and community settings, as well as proactive steps to 324 maintain life during social and economic lockdowns[3, 35]. Ethiopia, as with many 325 other African countries, has limited resources to deal with these outbreaks, and often 326 depends on international aid to help control and prevent these diseases [10, 36, 37].

³²⁷Over the course of four waves, we estimated 570 introductions and 446 exportation 328 events occurred. This is consistent with the relatively small number of lineages 329 identified during the study period, although could also be attributed to under and 330 sparse sampling that likely omitted lineages circulating at low prevalence. The short 331 generation time associated with RNA viruses could also imply that viruses circulating 332 during the period preceding the emergence of Omicron that became extinct would not ³³³have been detected. The phylogenetic inference and that of the geographical 334 distribution of the Ethiopian-emerging B.1.480 lineage suggest that Ethiopia serves as 335 a source for viral introductions not only to neighboring countries but also further 336 abroad. Ethiopia serves as a travel hub for this African region connecting this region in 337 Africa to neighboring countries and further abroad. Possible disease dissemination 338 was most likely a result of travel to and from Ethiopia via air, land, and waterways [37, 339 38]. Ethiopia is strategically located on the Red Sea, making it an important transit

340 point for goods moving between Africa, the Middle East, and Asia. The main 341 international airport in Ethiopia is Addis Ababa Bole International Airport facilitates 342 high travel volumes which most likely contributed to viral amplification in the country 343 followed by Ethiopian-originating viral exportation events. It is therefore imperative to ³⁴⁴have concerted, collaborative action to achieve pandemic mitigation.

345 We observed a reduction in the number of new deaths reported during the fourth
346 wave. This is consistent with the immunity acquired protection from a large number of wave. This is consistent with the immunity acquired protection from a large number of 347 infections from the preceding waves and increases in the total number of vaccinated ³⁴⁸individuals. A seroprevalence study among health care workers revealed a 349 seropositivity rate of 39.6% [39] while another study the estimated the prevalence rate 350 at over 50% [40]. However, only about 0.4% of the population has reportedly been
351 infected with COVID-19: much fewer than the estimated seroprevalence rates infected with COVID-19: much fewer than the estimated seroprevalence rates 352 estimated for the population. Therefore, taken together these statistics suggest that 353 case numbers may remain widely underreported. Reduced testing further hinders 354 effective genome surveillance as fewer samples were available to be subjected to 355 whole genome analyses and influences the accuracy of epidemiological conclusions 356 drawn.

357 In comparison to other countries, Ethiopia has very low vaccination coverage. As of ³⁵⁸December 2021, at least 1 000 000 Ethiopians had been vaccinated. It is important to 359 note that COVID-19 vaccines in Ethiopia were prioritized based on criteria such as 360 occupation, age, medical condition, people that work in aggregate settings, the elderly, 361 and people with comorbidities known to increase the risk of adverse COVID-19 ³⁶²outcomes[41]. Moreover, priority was given to those deemed as frontline medical staff, followed by non-frontline medical staff. This strategy was effective in slowing the 364 evolutionary rate of the virus as SARS-CoV-2 is prone to evolution in 365 immunosuppressed individuals experiencing chronic infection [42-44]. Vaccination has 366 also been shown to decrease the overall SARS-CoV-2 infection rate from 9.0% (95% 367 CrI: 8.4% – 9.4%) without vaccination to 4.6% (95% CrI: 4.3% – 5.0%) with the
368 bighest relative reduction noted among individuals aged 65 and above. Adverse highest relative reduction noted among individuals aged 65 and above. Adverse

369 outcomes, such as deaths, are reduced by approximately 69.3% (95% CrI: 65.5%-370 $\,$ 73.1%) with lowered vaccination coverage $[45]$.

371 Analysis of genomes and lineages across the study period highlighted the changes in 372 the population dynamics of the viral lineages circulating in Ethiopia. The B.1 and B.1.1 373 lineages dominated the first wave, persisted throughout the next two waves, and were 374 characterized by the well-known D614G mutation [46]. This mutation has been linked
375 to increased viral replication and transmissibility [38, 46]. Subsequent waves were to increased viral replication and transmissibility $[38, 46]$. Subsequent waves were 376 dominated by the VOCs Alpha, Beta, Delta, and Omicron. These VOCs evolved to ³⁷⁷evade overcome host immunity from infection with ancestral viruses and vaccination. ³⁷⁸By doing so these newly emerging variants fueled renewed infectious waves and were 379 often associated with increased transmissibility compared to their genetic 380 predecessors [47-49]. The Omicron variant (specifically, lineage BA.1.1) had a 381 reproduction number four times higher than Delta. It is considered the fifth variant of 382 concern first detected in November/December 2021 [50-53].

³⁸³One important lineage in the context of Ethiopia was the B.1.480, a distinct B lineage, 384 which emerged during the second wave. This variant was responsible for 2.77% of the 385 sampled cases. Notably, this variant was previously detected in passengers 386 originating from not only Ethiopia but also with those originating from European 387 countries such as the United Kingdom and France, as well as from travelers from ³⁸⁸United Arab Emeritus [50-53]). Unlike other VOCs, this lineage did not reach global 389 transmission and has only 473 submissions to the GISAID platform, however, it did 390 persist in Ethiopian populations for extended periods of time. Other worrisome ³⁹¹mutations carried by this lineage included the Spike mutation M1229I and D614G ³⁹²[46,47,49,54].

³⁹³In conclusion, the changing nature of the pandemic over time in Ethiopia has been 394 driven by lineage turnovers that, while dominated by VOCs and B.1.480, include other 395 lineages (A, B.1, B.1.1). Results from this study, and that of others (ref listed above), 396 showed that despite pandemic mitigation strategies implemented by the country, ³⁹⁷Ethiopia remained vulnerable to viral introduction events and served as a source of

398 viral introductions internationally. The COVID-19 pandemic is still ongoing and the
399 evolution of the virus is continuing to yield new variants some of which will likely reflect evolution of the virus is continuing to yield new variants some of which will likely reflect 400 altered viral behavior such as increased transmissibility, immune evasiveness, or 401 altered pathogenicity. It is therefore crucial that ongoing genomic surveillance be 402 strengthened and conducted to present real-time data generation to determine the 403 geographic distribution of these variants and enable the implementation of appropriate 404 disease methods in the mitigation strategies.

⁴⁰⁵**Acronyms /abbreviations**

⁴⁰⁷**Funding**

408 This research was financed by Addis Ababa University through the COVID-19-AAU 409 research fund for staff with a reference #- PR/5.15/590/12/20 and adaptive research 410 and problem-solving projects with Ref # AR/043/2021 and RD/PY-148/2021. Also, this 411 work was realized by the generous financial and technical support of the AU through 412 Africa CDC, PGI. No more external funding was received. The APC was funded by 413 Africa Pathogen Genomics Initiative (Africa PGI).

⁴¹⁴The funders had no role in the study design, data collection, analysis, decision to 415 publish, or preparation of the manuscript. The contents are purely the responsibilities 416 of the authors and did not represent and reflect the view of the founder.

⁴¹⁷**Author Contributions**

418 AS and AFD conceived and designed the experiments; AS, DT and SEJ performed 419 the data analysis and experiments; AS, DT, AFD and SEJ analyzed the data; GM, SO,

- ⁴²⁰SKT, CB, DM, RL, HT, MM, SvW, EW, TDO contributed materials/analysis tools; AT,
- 421 AFD and SEM supervise the work; AS, DT, SvW and SEJ wrote the paper. All
- 422 authors read the final version of the manuscript.

⁴²³**Informed Consent Statement**

⁴²⁴All participants gave written informed consent for participation and publication.

⁴²⁵**Declaration of Competing Interest**

⁴²⁶We all the authors declare that we have no known competing interests or personal 427 relationships that could have appeared to influence the work reported in this research 428 paper.

⁴²⁹**Data availability**

430 All the generated sequences used for this manuscript have been deposited in the 431 GISAID sequence database and are purely publicly available. However, it's subject to 432 the terms and conditions of the GISAID database, https://www.gisaid.org/, GISAID 433 Identifier: EPI_SET_221214bg, DOI: 10.55876/gis8.221214bg.

⁴³⁴**Acknowledgment**

⁴³⁵We would like to acknowledge Addis Ababa University for giving us the opportunity 436 and financing the research. This work is realized with the generous financial and 437 technical support of Africa CDC, PGI

- ⁴³⁸We are very grateful and acknowledge the CERI and KRISP (South Africa) & ILRI 439 (Kenya) for supporting this work by performing the whole genomic sequencing.
- ⁴⁴⁰We also wish to extend our gratitude to Arsho Medical Laboratories for supporting this 441 research by giving us a -80 $^{\circ\circ}$ refrigerator for centrally storing our specimens.
- ⁴⁴²Last but not least we are very glad and thankful to Retina Pharmaceutical for 443 supporting this work by availing required pharmaceutical inquiries.
- 444
-
-

⁴⁴⁸**Reference**

⁴⁷⁶Ethiopia. *Front Public Health*. 2022;10: 834592. Published 2022 May 11. ⁴⁷⁷doi:10.3389/fpubh.2022.834592

- 478 11. Leulseged TW, Abebe KG, Hassen IS, et al. COVID-19 disease severity and 479 associated factors among Ethiopian patients: A study of the millennium COVID-
- ⁴⁸⁰19 care center. *PLoS One*. 2022;17(1):e0262896. Published 2022 Jan 27. ⁴⁸¹doi:10.1371/journal.pone.0262896
- 482 12. Abdella S, Riou S, Tessema M, et al. Prevalence of SARS-CoV-2 in urban and 483 **Fural Ethiopia: Randomized household serosurveys reveal level of spread** ⁴⁸⁴during the first wave of the pandemic. *EClinicalMedicine*. 2021; 35:100880. ⁴⁸⁵Published 2021 May 7. doi:10.1016/j.eclinm.2021.100880
- ⁴⁸⁶13. Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high 487 throughput. Nucleic acids research. 2004;32(5):1792-7.
- ⁴⁸⁸14. Sisay A, Abera A, Dufera B, Endrias T, Tasew G, Tesfaye A, et al. Diagnostic 489 **Accuracy of three commercially available one step RT-PCR assays for the** 490 detection of SARS-CoV-2 in resource limited settings. PloS one. 2022; 491 **17(1):e0262178.**
- 492 15. MOLBIOL T. RT-PCR test kits and VirSNiP Mutation Assays for strain ⁴⁹³surveillance [Available from: https://www.tib-molbiol.de/covid-19.
- ⁴⁹⁴16. World Health Organization W. Emergency Use Listing Procedure for in vitro 495 diagnostics 2020 [Available from: https://www.who.int/teams/regulation-496 prequalification/eul/in-vitro-emergency-use-listing-procedure.
- ⁴⁹⁷17. BGI. Real-Time Fluorescent RT-PCR Kit for Detecting SARS-CoV-2 2020 498 [Available from: https://www.bgi.com/us/sars-cov-2-real-time-fluorescent-rt-pcr-499 kit-ivd/
- 500 18. Tshiabuila D, Giandhari J, Pillay S, et al. Comparison of SARS-CoV-2 501 **Sequencing using the ONT GridION and the Illumina MiSeq.** *BMC Genomics***.** ⁵⁰²2022; 23(1):319. Published 2022 Apr 22. doi:10.1186/s12864-022-08541-5
- 503 19. Pembaur A, Sallard E, Weil PP, Ortelt J, Ahmad-Nejad P, Postberg J. 504 Simplified Point-of-Care Full SARS-CoV-2 Genome Sequencing Using 505 Nanopore Technology. Microorganisms. 2021; 9(12).

⁵⁰⁶20. Vilsker M, Moosa Y, Nooij S, et al. Genome Detective: an automated system for 507 virus identification from high-throughput sequencing data. *Bioinformatics*. ⁵⁰⁸2019;35(5):871-873. doi:10.1093/bioinformatics/bty695

- 509 21. Cleemput S, Dumon W, Fonseca V, et al. Genome Detective Coronavirus 510 Typing Tool for rapid identification and characterization of novel coronavirus
511 oenomes. *Bioinformatics*. 6. [2020] 12020:36(11):3552-3555. ⁵¹¹genomes. *Bioinformatics*. 2020;36(11):3552-3555.
- 512 doi:10.1093/bioinformatics/btaa145
- ⁵¹³22. Larsson A. AliView: a fast and lightweight alignment viewer and editor for large 514 datasets. Bioinformatics (Oxford, England). 2014; 30(22):3276-8.
- 515 23. Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high 516 throughput. Nucleic acids research. 2004; 32(5):1792-7.
- 517 24. Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data -518 from vision to reality. Euro surveillance: bulletin Europeen sur les maladies 519 **transmissibles = European communicable disease bulletin. 2017;22(13).**
- ⁵²⁰25. Nextclade. Next clade. https://clades.nextstrain.org/ 2021 [Available from: 521 https://clades.nextstrain.org/.
- 522 26. Aksamentov I., Neher R. Nextalign: Viral Genome Reference Alignment. 523 [(accessed on 16 Jan 2023]. Available 524 online: https://github.com/neherlab/nextalign
- ⁵²⁵27. Minh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, von 526 Haeseler A, Lanfear R. IQ-TREE 2: New Models and Efficient Methods for 527 **Phylogenetic Inference in the Genomic Era. Mol Biol Evol. 2020 May** 528 1;37(5):1530-1534. doi: 10.1093/molbev/msaa015.
- 529 28. Gatto L, Catanzaro D, Milinkovitch MC. Assessing the applicability of the GTR 530 nucleotide substitution model through simulations. *Evol Bioinform Online*. ⁵³¹2007;2:145-155. Published 2007 Feb 4.
- 532 29. Pavel Sagulenko, Vadim Puller, Richard A Neher, TreeTime: Maximum-⁵³³likelihood phylodynamic analysis, *Virus Evolution*, Volume 4, Issue 1, January 534 2018, vex042, https://doi.org/10.1093/ve/vex042

535 30. Yu G, Smith DK, Zhu H, Guan Y, Lam TT-Y. ggtree: an r package for 536 visualization and annotation of phylogenetic trees with their covariates and 537 other associated data. Methods in Ecology and Evolution. 2017;8(1):28-36. 538 31. Ellingjord-Dale, M., Kalleberg, K.T., Istre, M.S. *et al.* The use of public transport 539 and contraction of SARS-CoV-2 in a large prospective cohort in Norway. *BMC* ⁵⁴⁰*Infect Dis* 22, 252 (2022). https://doi.org/10.1186/s12879-022-07233-5 541 32. Mekuriaw W, Kinde S, Kindu B, Mulualem Y, Hailu G, Gebresilassie A, et.,al. ⁵⁴²Epidemiological, Entomological, and Climatological Investigation of the 2019 543 **Dengue Fever Outbreak in Gewane District, Afar Region, North-East** ⁵⁴⁴Ethiopia. *Insects*. 2022; 13(11):1066. https://doi.org/10.3390/insects13111066 545 33. Mengesha Tsegaye, M., Beyene, B., Ayele, W. *et al.* Sero-prevalence of yellow ⁵⁴⁶fever and related Flavi viruses in Ethiopia: a public health perspective. *BMC* ⁵⁴⁷*Public Health* **¹⁸**, 1011 (2018). https://doi.org/10.1186/s12889-018-5726-9 548 34. Tegally H, San JE, Cotten M, et al. The evolving SARS-CoV-2 epidemic in ⁵⁴⁹Africa: Insights from rapidly expanding genomic surveillance. *Science*. ⁵⁵⁰2022;378(6615):eabq5358. doi:10.1126/science.abq5358 551 35. Abagero A, Ragazzoni L, Hubloue I, Barone-Adesi F, Lamine H, Addissie A, 552 **Della Corte F, Valente M. A Review of COVID-19 Response Challenges in** ⁵⁵³Ethiopia. *Int. J. Environ. Res. Public Health.* 2022; 19(17):11070. ⁵⁵⁴https://doi.org/10.3390/ijerph191711070 ⁵⁵⁵36. Tessema GA, Kinfu Y, Dachew BA, Tesema AG, Assefa Y, Alene KA, et al. 556 The COVID-19 pandemic and healthcare systems in Africa: a scoping review of 557 preparedness, impact and response. BMJ global health. 2021;6(12):e007179. 558 37. Nigussie H. The Coronavirus Intervention in Ethiopia and the Challenges for 559 **Implementation. Front. Commun., 21 May 2021 Sec. Health Communication** 560 Volume 6 – 2021. https://doi.org/10.3389/fcomm.2021.562512 561 38. Ngeh S, Vogt F, Sikazwe CT, et al. Travel-associated SARS-CoV-2 562 **transmission documented with whole genome sequencing following a long-haul** ⁵⁶³international flight. *J Travel Med*. 2022;29(6):taac057. doi:10.1093/jtm/taac057

39. Gelanew T, Seyoum B, Mulu A, et al. High seroprevalence of anti-SARS-CoV-2 antibodies among Ethiopian healthcare workers. *BMC Infect Dis*. 2022;22(1):261. Published 2022 Mar 16. doi:10.1186/s12879-022-07247-z

- 567 40. Gudina EK, Ali S, Girma E, et al. Seroepidemiology and model-based prediction of SARS-CoV-2 in Ethiopia: longitudinal cohort study among front-line hospital workers and communities. *Lancet Glob Health*. 2021;9(11):e1517- e1527. doi:10.1016/S2214-109X(21)00386-7
- 41. COVID-19 Vaccine tracker. https://www.reuters.com/graphics/world-572 coronavirus-tracker-and-maps/vaccination-rollout-and-access/
- 42. Kemp, S.A., Collier, D.A., Datir, R.P. *et al.* SARS-CoV-2 evolution during **treatment** of chronic infection. Nature 592, 277–282 https://doi.org/10.1038/s41586-021-03291-y
- 43. Wilkinson SAJ, Richter A, Casey A, Osman H, Mirza JD, Stockton J, et al. 577 Recurrent SARS-CoV-2 mutations in immunodeficient patients. Virus evolution. 578 2022;8(2): veac050.
- 44. Weigang, S., Fuchs, J., Zimmer, G. *et al.* Within-host evolution of SARS-CoV-2 580 in an immunosuppressed COVID-19 patient as a source of immune escape variants. *Nat Commun* 12, 6405 (2021). https://doi.org/10.1038/s41467-021- 26602-3
- 45. Moghadas SM, Vilches TN, Zhang K, et al. The impact of vaccination on COVID-19 outbreaks in the United States. Preprint. *medRxiv*. 2021;2020.11.27.20240051. Published 2021 Jan 2. doi:10.1101/2020.11.27.20240051
- 46. Korber B, Fischer WM, Gnanakaran S, et al. Tracking Changes in SARS-CoV-2 588 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. *Cell.* 2020;182(4):812-827.e19. doi:10.1016/j.cell.2020.06.043
- 47. Harvey, W.T., Carabelli, A.M., Jackson, B. *et al.* SARS-CoV-2 variants, spike mutations and immune escape. *Nat Rev Microbiol* 19, 409–424 (2021). 592 https://doi.org/10.1038/s41579-021-00573-0
- 48. Liu Y, Rocklöv J. The reproductive number of the Delta variant of SARS-CoV-2 594 is far higher compared to the ancestral SARS-CoV-2 virus. J Travel Med. 2021

Oct 11;28(7):taab124. doi: 10.1093/jtm/taab124. PMID: 34369565; PMCID: 596 PMC8436367.

- 49. Thakur S, Sasi S, Pillai SG, et al. SARS-CoV-2 Mutations and Their Impact on **Diagnostics, Therapeutics and Vaccines.** *Front Med (Lausanne)***. 2022;9:** 815389. Published 2022 Feb 22. doi:10.3389/fmed.2022.815389
- 50. Shrivastava S, Mhaske ST, Modak MS, Virkar RG, Pisal SS, Mishra AC, et al. Emergence of two distinct variants of SARS-CoV-2 and an explosive second wave of COVID-19: the experience of a tertiary care hospital in Pune, India. Archives of virology. 2022; 167(2):393-403.
- 51. Dhama K, Nainu F, Frediansyah A, Yatoo MI, Mohapatra RK, Chakraborty S, et 605 al. Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies. Journal of Infection and Public Health. 2023; 16(1):4-14.
- 52. Zhou Y, Zhi H, Teng Y. The outbreak of SARS-CoV-2 Omicron lineages, immune escape, and vaccine effectivity. *J Med Virol*. 2022;10.1002/jmv.28138. doi:10.1002/jmv.28138
- 53. Corriero A, Ribezzi M, Mele F, Angrisani C, Romaniello F, Daleno A, et., al. COVID-19 Variants in Critically Ill Patients: A Comparison of the Delta and Omicron Variant Profiles. *Infectious Disease Reports*. 2022; 14(3):492-500. https://doi.org/10.3390/idr14030052
- 54. Dubey, A., Choudhary, S., Kumar, P. *et al.* Emerging SARS-CoV-2 Variants: Genetic Variability and Clinical Implications. *Curr Microbiol* **⁷⁹**, 20 (2022). https://doi.org/10.1007/s00284-021-02724-1
-
-
-
-
-

It is made available under a CC-BY-NC 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.01.30.23285174;](https://doi.org/10.1101/2023.01.30.23285174) this version posted January 31, 2023. The copyright holder for this preprint

⁶²⁵**Tables, Figures and Supplementary Files**

⁶²⁶**Table 1**. Socio-demographic characteristics of study participants along with VOC of SARS-CoV-2 in ⁶²⁷Ethiopia, 2020-2022.

Variable	Class	Frequency $(\%)$	Variant (VOC)			
			Alpha	Beta	Delta	Omicron
Sex	Female	181 (51.3)	10	2	99	57
	Male	172 (48.7)	7		102	46
Age Range	$1 - 20$	40 (11.3)			19	8
(years)	$21 - 30$	121 (34.3)			80	25
	$31 - 40$	84 (23.8)	5		43	30
	41-50	41 (11.6)	2	0	25	12
	$51 - 60$	21(10.2)	2	0	18	15
	>60	31(8.8)	$\mathbf 0$	0	16	13
Reason for	Suspect	107 (30.3)	6		133	2
testing	Contacts of	79 (22.4)	8	$\overline{2}$	45	
(during	confirmed cases					
sampling)	Community	167 (47.3)	3	Ω	23	100
	Surveillance					
Clinical	Asymptomatic*	53(15)	3	Ω	37	5
Status of the	Mild	273 (77.3)	14	3	142	94
clients while sampling	Sever	27(7.7)	0	0	22	4

⁶²⁸ $*$ Asymptomatic – a person has tested positive for COVID-19 but never exhibits any signs or symptoms of the 629 disease disease

630 *Figure 1: SARS-CoV-2 epidemiology and variant turnover in Ethiopia: (a) 7-day rolling average for the number of new SARS-CoV-2 cases. Others, represented in blue, comprise mostly B lineages including B, B.1, and B.1.1 lineages. The size of the dot is indicative of the variant proportion in the population. (b) The proportion of individuals that have received at least one vaccine dose in Ethiopia compared to the number of new deaths that occurred. (c)*

⁶³⁶*Summary of the mean number of detected introductions into Ethiopia binned by month for* ⁶³⁷*different regions across the dataset. (d) Summary of the mean number of detected* exportations out of Ethiopia to different regions binned by month.

⁶³⁹*Figure 2: SARS-CoV-2 lineage diversity in Ethiopia. (A) Proportions of SARS-CoV-2 lineages,*

⁶⁴⁰*classified by Pangolin nomenclature, circulating between June 2020 and February 2022 in*

- ⁶⁴¹*Ethiopia. (B) Absolute counts of SARS-CoV-2 genomes throughout the study period. Only*
- ⁶⁴²*VOCs and major lineages are listed in the legend. (C) Maximum-Likelihood phylogeny of 353*

⁶⁴³*SARS-CoV-2 genomes. Branches are colored by lineage.*

644

646

⁶⁴⁷**List of Supplementary Files**

- 648 Table S1- Timeline of COVID-19 and major events following the first confirmed cases
- 649 in Ethiopia
- 650 Figure S2- Consortium Diagram of Sampling for Molecular Epidemiology and Diversity
651 of SARS-CoV-2 in Ethiopia
- of SARS-CoV-2 in Ethiopia
- 652 Figure S3- The sampling area covers in Ethiopia
- 653 Figure S4-Major SARS-CoV-2 lineages of detected imported and exported Ethiopia
654 between June 2020 and February 2022
- between June 2020 and February 2022
- 655 Figure S5- SARS-CoV-2 Delta VOC sub tree molecular clock, Ethiopia.

686 Table S1 Summary of the COVID-19 timeline and major events following the first confirmed cases in Ethiopia

confirmed cases in Ethiopia

689 center during this time

690

It is made available under a CC-BY-NC 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.01.30.23285174;](https://doi.org/10.1101/2023.01.30.23285174) this version posted January 31, 2023. The copyright holder for this preprint

-
- 713
714
- יני
715
- 715

716 Figure - S3a- Sampling area for Molecular Epidemiology and Diversity of SARS-CoV-2 in Ethiopia

717
718 Table S3b: Sequence proportion of the regional government

722

724

725 Figure S 4-Major SARS-CoV-2 lineages of detected imported and exported Ethiopia between June

726 2020 and February 2022

727

728

⁷³⁰**Figure S 5 -** SARS-CoV-2 Delta VOC sub tree molecular clock, Ethiopia.

-
-
- ----
733

738 738

of Ethiòṗia to different regions binned by month.

